Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity

Trends in Biotechnology

Volumn 18, Issue 11, 2000, Pages 462-468

  Kuwabara, Tomoko ^a   Warashina, Masaki ^a   Taira, Kazunari ^b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAXIZYME; MESSENGER RNA; RIBOZYME; UNCLASSIFIED DRUG;

ALLOSTERISM; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE CONSTRUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA CLEAVAGE;

ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BIOSENSING TECHNIQUES; BIOTECHNOLOGY; FUSION PROTEINS, BCR-ABL; HUMAN; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; RNA, CATALYTIC; RNA, MESSENGER; SUBSTRATE SPECIFICITY;

EID: 0034333199     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(00)01498-0     Document Type: Review

References (69)

1. The hammerhead RNA domain, a model ribozyme
2. Role of divalent metal ions in the hammerhead RNA cleavage reaction
3. Metal ion catalysis in the Tetrahymena ribozyme reaction
4. Ribozymes: a distinct class of metalloenzymes
5. A general two-metal-ion mechanism for catalytic RNA
6. 2+ ions in ribozyme reactions
7. How many catalytic RNAs? Ions and the Cheshire cat conjecture
8. Theoretical and experimental considerations on the hammerhead ribozyme reactions: divalent magnesium-ion mediated cleavage of phosphorus-oxygen bonds
9. Kinetic evidence based on solvent isotope effects for the nonexistence of a proton-transfer process in reactions catalysed by a hammerhead ribozyme: implication to the double-metal-ion mechanism of catalysis
10. Evidence for the rate-limiting departure of the 59-oxygen in nonenzymatic and hammerhead ribozyme-catalysed reactions
11. The hammerhead ribozyme-structure, function and application
12. A second catalytic metal ion in group I ribozyme
13. Explanation by the double-metal-ion mechanism of catalysis for the differential metal ion effects on the cleavage rates of 59-oxy and 59-thio substrates by a hammerhead ribozyme
14. A two-metal ion mechanism operates in the hammerhead ribozyme-mediated cleavage of an RNA substrate
15. The hammerhead, hairpin and VS ribozymes are catalytically proficient in monovalent cations alone
16. The hydrolysis of RNA: from theoretical calculations to the hammerhead ribozyme-mediated cleavage of RNA
17. A further investigation and reappraisal of the thio effect in the cleavage reaction catalysed by a hammerhead ribozyme
18. A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability
19. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo
20. Enhancement of the cleavage rates of DNA-armed hammerhead ribozymes by various divalent metal ions
21. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages
22. Entropically driven enhancement of cleavage activity of a DNA-armed hammerhead ribozyme: mechanism of action of hammerhead ribozymes
23. Minimal sequence requirements for ribozyme activity
24. Hammerhead ribozymes: importance of stem-loop II activity
25. Hammerhead ribozymes containing non-nucleoside linkers are active RNA catalysts
26. Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions
27. Hammerhead minizymes with high cleavage activity: a dimeric structure as the active conformation of minizymes
28. Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes
29. Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes
30. Novel tRNAVal-heterodimeric maxizymes with high potential as gene-inactivating agents: Simultaneous cleavage at two sites in HIV-1 tat mRNA in cultured cells
31. CTAB-mediated enrichment for active forms of novel dimeric maxizymes
32. Cleavage of specific sites of RNA by designed ribozymes
33. Mutagenesis analysis of a self-cleaving RNA
34. Sequence requirements of the hammerhead RNA self-cleavage reaction
35. Extended target-site specificity for a hammerhead ribozyme
36. Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes
37. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes
38. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule
39. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
40. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia
41. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukemia
42. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
43. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line
44. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
45. Treatment of chronic myelogenous leukemia with bone marrow transplantation
46. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program
47. Genetic marking shows that Ph1 cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
48. Induction of chronic myelogenous leukemia in mice by the P210(bcr/abl) gene of the Philadelphia chromosome
49. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro
50. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo
51. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA
52. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA
53. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization
54. Expression of small, therapeutic RNAs in human cell nuclei
55. Efficient ex vivo inhibition of perforin and Fas ligand expression by chimeric tRNA-hammerhead ribozymes
56. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III
57. RNA enzymes (ribozymes) as antiviral therapeutic agents
58. Ribozymes as potential anti-HIV-1 therapeutic agents
59. Controlled, targeted, intracellular expression of ribozymes: progress and problems
60. Oncogene inactivation in a mouse model: tissue invasion by leukaemic cells is stalled by loading them with a designer ribozyme
61. Maxizymes, novel allosterically controllable ribozymes can be designed to cleave various substrates
62. Nucleic acids molecular switches
63. Training ribozymes to switch
64. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression
65. Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme